Viking Therapeutics has a dual GLP-1/GIP agonist in Phase 3 with 4,500+ patients enrolled

Statements (3)

1. ● Neutral

   Viking Therapeutics reported a successful weight-loss drug trial addressing GLP-1 therapy weakness.

   thedailyupside.comSep 23, 2026 04:01 UTC
2. ▲ Bullish

   Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data

   247wallst.comSep 22, 2026 17:20 UTCHigh importance
3. ▲ Bullish

   Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly's Zepbound.

   marketwatch.comSep 22, 2026 15:46 UTC